NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.16 Million USD | 54.94% |
| 2022 | -61.58 Million USD | -19.3% |
| 2021 | -52.39 Million USD | -93.18% |
| 2020 | -27.12 Million USD | -32.63% |
| 2019 | -20.44 Million USD | -56.84% |
| 2018 | -13.03 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.5 Billion USD | -0.45% |
| 2024 Q1 | -2.64 Million USD | 23.71% |
| 2023 Q4 | -4.44 Million USD | 55.5% |
| 2023 Q3 | -9.99 Million USD | -32.97% |
| 2023 Q1 | -9.56 Million USD | 42.5% |
| 2023 Q2 | -7.51 Million USD | 21.38% |
| 2023 FY | - USD | 54.94% |
| 2022 Q3 | -14.46 Million USD | 7.36% |
| 2022 Q2 | -15.61 Million USD | -5.55% |
| 2022 Q1 | -14.79 Million USD | 3.18% |
| 2022 FY | - USD | -19.3% |
| 2022 Q4 | -16.62 Million USD | -14.93% |
| 2021 Q1 | -9.89 Million USD | -44.29% |
| 2021 FY | - USD | -93.18% |
| 2021 Q4 | -15.28 Million USD | -0.17% |
| 2021 Q3 | -15.25 Million USD | -27.53% |
| 2021 Q2 | -11.96 Million USD | -20.92% |
| 2020 Q2 | -6.59 Million USD | -6.95% |
| 2020 Q1 | -6.17 Million USD | -15.65% |
| 2020 FY | - USD | -32.63% |
| 2020 Q4 | -6.85 Million USD | 8.52% |
| 2020 Q3 | -7.49 Million USD | -13.56% |
| 2019 Q4 | -5.33 Million USD | 0.0% |
| 2019 FY | - USD | -56.84% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -6197.343% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 4.536% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 75.303% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -78.717% |
| Better Therapeutics, Inc. | -38.26 Million USD | 26.383% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 26.388% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -57.478% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 16.499% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 15.598% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 73.513% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -2983.562% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 13.283% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 39.674% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -395.58% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -72.794% |
| Molecular Templates, Inc. | 1.43 Million USD | 2069.756% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -103.008% |
| Orgenesis Inc. | -60.71 Million USD | 53.609% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 45.086% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -38266.991% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -74.463% |
| Scopus BioPharma Inc. | -11.71 Million USD | -140.478% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 94.783% |
| Statera Biopharma, Inc. | 38.93 Million USD | 172.345% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -309.174% |
| Trevena, Inc. | -35.28 Million USD | 20.178% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -50153.359% |
| Vaccinex, Inc. | -19.74 Million USD | -42.635% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -2590.363% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 39.893% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -287.821% |